EAM
RYTM icon

Exome Asset Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Exome Asset Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-40,000
Closed -$70K – 79
2025
Q1 		$70K Buy
+40,000
New +$2.22M 0.06% 53

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Exome Asset Management's RYTM Position: Q2 2026 in Review

Exome Asset Management reduced its Rhythm Pharmaceuticals (RYTM) stake by 21% in Q2 2026, selling an estimated $757K and leaving 32,209 shares worth $3.58M. The position accounts for 2.21% of the portfolio, ranked #16.

Exome Asset Management first reported a position in RYTM in Q4 2023 and has held it in 4 quarters since. 305 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Exome Asset Management held 32,209 shares of Rhythm Pharmaceuticals worth $3.58M as of Q2 2026.
  • Exome Asset Management sold 8,372 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $757K.
  • Rhythm Pharmaceuticals made up 2.21% of Exome Asset Management's portfolio in Q2 2026, its #16 holding.
  • Exome Asset Management first reported a position in Rhythm Pharmaceuticals in Q4 2023 and has held it in 4 quarters since.
  • 305 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Exome Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.